Autolus Therapeutics plc
AUTL · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $1 | $0 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $1 | $0 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 1.3% | 132.9% | 30,872.4% | – |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | -35.1% | -16.8% | -99.9% | -476,810.3% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -305.3% | -272% | -618.1% | -254,437.9% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -373.3% | -229% | -781.1% | -95,193.1% |
| EPS Diluted | -0.3 | -0.18 | -0.26 | -0.1 |
| % Growth | -66.7% | 30.8% | -160% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |